Nova Pharma Solutions Bhd (XKLS:03006) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Nova Pharma Solutions Bhd LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nova Pharma Solutions Bhd's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Nova Pharma Solutions Bhd's long-term debt to total assets ratio declined from Dec. 2022 (0.01) to Dec. 2023 (0.00). It may suggest that Nova Pharma Solutions Bhd is progressively becoming less dependent on debt to grow their business.

Nova Pharma Solutions Bhd LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nova Pharma Solutions Bhd's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Pharma Solutions Bhd LT-Debt-to-Total-Asset Chart

Nova Pharma Solutions Bhd Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Nova Pharma Solutions Bhd Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial											-	-	0.01	0.01	-

Nova Pharma Solutions Bhd LT-Debt-to-Total-Asset Calculation

Nova Pharma Solutions Bhd's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.041	/	17.337
	=	0.00

Nova Pharma Solutions Bhd's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0.041	/	17.337
	=	0.00

Nova Pharma Solutions Bhd (XKLS:03006) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nova Pharma Solutions Bhd LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nova Pharma Solutions Bhd's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Pharma Solutions Bhd (XKLS:03006) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Construction » Nova Pharma Solutions Bhd (XKLS:03006) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

Jalan USJ 25/1, Level 5, Suite C-5-1 & 2, Block C, Sky Park, One City, Subang Jaya, SGR, MYS, 47650

Website

http://www.novapharmasolutions.com

Nova Pharma Solutions Bhd provides engineering solutions to pharma and biotech industries. The company's reportable segments include Design fee, Post Design, & Other support fees. Design fee comprises conceptual designs which include user requirement specification, capacity analysis and process scheduling with detailed costing, list of deliverables, details specification of various equipment and processes. Post design fee comprise tendering and procurement support as well as the construction of a plant, & Other support fees comprise of services to assist a customer in the good manufacturing practice document review & gap analysis and assessment. It generates a majority of its revenue from the Design fee segment. Geographically, the company generates a majority of its revenue from Malaysia.

Nova Pharma Solutions Bhd (XKLS:03006) Headlines

No Headlines